Company: TVRD
Filing Date: 2025-02-14
Form Type: S-4/A
Source: 0001104659-25-013053
Chunk: 629

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: S-4/A
Chunk 629
---
’s cash equivalents, it believes an immediate 10% change in interest rates would not have a material effect on their fair market value. Effects of Inflation Inflation generally affects Tvardi by increasing the cost of labor and research and development contract costs. Tvardi does not believe inflation has had a material effect on its results of operations during the periods presented in its financial statements included elsewhere in this proxy statement/prospectus. Foreign Currency Exchange Risk All of Tvardi’s employees and its operations are currently located in the United States, and expenses are generally denominated in U.S. dollars. As such, Tvardi is not exposed to financial risks from exchange rate fluctuations between U.S. dollars and other currencies.

359

TABLE OF CONTENTS

MANAGEMENT FOLLOWING THE MERGER The following table provides information regarding the expected directors and executive officers of the combined company following the closing of the Merger:

| Name                        | ​ | ​ | Age | ​ | ​ | Position                                              | ​ |
| Imran Alibhai, Ph.D.        | ​ | ​ |  48 | ​ | ​ | Chief Executive Officer and Director                  | ​ |
| Dan Conn, J.D., M.B.A.      | ​ | ​ |  57 | ​ | ​ | Chief Financial Officer                               | ​ |
| John Kauh, M.D.             | ​ | ​ |  51 | ​ | ​ | Chief Medical Officer                                 | ​ |
| Jeffrey Larson, Ph.D., DABT | ​ | ​ |  63 | ​ | ​ | Senior Vice President, Research & Development         | ​ |
| Yixin “Joseph” Chen, Ph.D.  | ​ | ​ |  64 | ​ | ​ | Vice President, Chemistry, Manufacturing and Controls | ​ |
| Sujal Shah                  | ​ | ​ |  51 | ​ | ​ | Chairman of the Board                                 | ​ |
| Wallace Hall                | ​ | ​ |  62 | ​ | ​ | Director                                              | ​ |
| Shaheen Wirk, M.D.          | ​ | ​ |  47 | ​ | ​ | Director                                              | ​ |
| Michael Wygza               | ​ | ​ |  69 | ​ | ​ | Director                                              | ​ |

Executive Officers Imran Alibhai, Ph.D. has served as Tvardi’s Chief Executive Officer and a member of its board of directors since December 2018. Since 2018, Dr. Al